Zacks: Analysts Expect Clearside Biomedical Inc (NASDAQ:CLSD) to Announce -$0.16 Earnings Per Share

Analysts predict that Clearside Biomedical Inc (NASDAQ:CLSD) will report ($0.16) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Clearside Biomedical’s earnings, with estimates ranging from ($0.18) to ($0.15). Clearside Biomedical posted earnings of ($0.75) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 78.7%. The business is scheduled to issue its next quarterly earnings results on Thursday, November 14th.

According to Zacks, analysts expect that Clearside Biomedical will report full year earnings of ($0.91) per share for the current year, with EPS estimates ranging from ($0.95) to ($0.88). For the next financial year, analysts expect that the firm will post earnings of ($0.42) per share, with EPS estimates ranging from ($0.63) to ($0.12). Zacks’ earnings per share calculations are an average based on a survey of research firms that follow Clearside Biomedical.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.15) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.22. The firm had revenue of $0.05 million for the quarter, compared to the consensus estimate of $0.05 million.

A number of research firms recently commented on CLSD. Wedbush reiterated a “buy” rating and set a $3.00 price target on shares of Clearside Biomedical in a report on Monday. Zacks Investment Research upgraded shares of Clearside Biomedical from a “hold” rating to a “strong-buy” rating and set a $1.00 price target for the company in a report on Tuesday. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Needham & Company LLC lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Friday, August 9th. Finally, Laidlaw lowered shares of Clearside Biomedical from a “buy” rating to a “hold” rating in a report on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. Clearside Biomedical has a consensus rating of “Hold” and a consensus price target of $3.43.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Jane Street Group LLC bought a new position in Clearside Biomedical in the 2nd quarter worth $98,000. Paloma Partners Management Co bought a new position in Clearside Biomedical in the 2nd quarter worth $122,000. Vanguard Group Inc. raised its holdings in Clearside Biomedical by 66.9% in the 2nd quarter. Vanguard Group Inc. now owns 924,485 shares of the company’s stock worth $899,000 after purchasing an additional 370,690 shares in the last quarter. Finally, A.R.T. Advisors LLC bought a new position in Clearside Biomedical in the 2nd quarter worth $95,000. Institutional investors and hedge funds own 11.95% of the company’s stock.

NASDAQ:CLSD traded up $0.15 during midday trading on Wednesday, reaching $0.94. 3,541,789 shares of the stock traded hands, compared to its average volume of 784,938. The company has a fifty day moving average of $0.74 and a 200 day moving average of $1.03. Clearside Biomedical has a 12 month low of $0.56 and a 12 month high of $6.27. The company has a debt-to-equity ratio of 0.69, a quick ratio of 3.47 and a current ratio of 3.47. The stock has a market capitalization of $30.91 million, a P/E ratio of -0.35 and a beta of -0.57.

About Clearside Biomedical

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

See Also: What is a capital gain?

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.